Intrathecal Drug Delivery System market, by Product Type (Externalized and connected to a pump and Fully Implanted), By Application (Pain Management and Spasticity Management): Global Opportunity Analysis and Industry Forecast, 2020-2027
- RES4072087
- 110 Pages
- February 2020
- Healthcare
Intrathecal drugs delivery system plays the substantial role in the treatments of intractable pain. IDD system utilized for selected patients which are associated with significant decrease in quality of health and that have not options of any other treatment. This treatment involves skilled expertise for ensuring proper selection along with the safety criteria.
IDD enables therapist to formulate individualized treatment regimens which can provide improved analgesia with small doses coupled with fewer adverse effects over opioid-based therapies.
Intrathecal Drug Delivery (ITDD) enable clinicians to formulate individualized treatment regimens that can provide significantly improved analgesia (pain relief) with smaller doses, and fewer adverse effects than traditional opioid-based (morphine & morphine - like) therapies where other techniques have failed or are not indicated, thus driving the growth of Intrathecal Drug Delivery System market.
Rising demand for intrathecal drug delivery system for cancer pain. Moreover cost–effective cancer pain treatment is yet another factor which drives the growth of the intrathecal drug delivery system market across the globe. Besides, complications of ITDD systems is the factor that is expected to hamper the growth of this market. Moreover, growing acceptance for IT therapy worldwide is expected to offer lucrative opportunities for the global ITDD system market during the forecast period.
The global Intrathecal Drug Delivery System market is segment based on product type, Application, and region. Depending on product type the market is divided into on externalized and connected to a pump and fully implanted. Externalized and connected to a pump has the highest market share and is expected to grow with the a CAGR of 7.1%, generated revenue of $801.9 million by the end of 2019 and it will reach upto $1,358.6 million in 2027. Externalized and connected with a pump is used in situations wherein there’s frequent need of change of catheter such as those who are suffering from cancer. They are in trend as they are cost effective compared to fully implanted systems.
These pumps have proved to be very effective for cancer pain and have been use since the last 3-4 decades and they are still in use as fully implanted systems are still in R&D phase and are not use in major developing countries.
By Application, Intrathecal Drug Delivery System market is categorized into Pain Management and Spasticity Management. Spasticity Management contributes the most among the application segment. Spasticity Management registered revenue of $668.0 million by the end of 2019, and is anticipated to reach upto $1,140.2 million by 2027. ITDD devices are mostly used for spasticity management and with the advent of fully programmable systems the spasticity is managed by controlling the flow of drug delivery, thus driving the growth of Intrathecal Drug Delivery System Market.
North America has the highest market share for Intrathecal Drug Delivery Systems globally and is expected to grow at a healthy rate of 7.4% generating revenue of $695.9 million for 2027. In North America the growth of fully implanted Intrathecal drug device is on the rise due to ease of usage which signifies better control and long-lasting nature of the Intrathecal devices. Thus, this is one of the major driving factors for Intrathecal drug devices. Spasticity management is also one of the major reasons why an ITDD system is growing in North America.
U.S, hold the majority of the share of the North America market and it is one of the leading countries globally. Companies are spending heavily on research & Development activities, inorder to provide innovative and effective pain management solution thereby driving the growth of Intrathecal Drug delivery systems in the country. For example, In U.S, the FDA approved the Medtronic Company’s new SynchroMed II myPTM Personal Therapy Manager for patients with chronic pain. The company said the device "enables patients to alleviate their unpredictable pain by delivering on-demand boluses, or drug doses, within therapeutic limits set by their physician.
Some of the prominent manufacturers of Intrathecal drug delivery system include Flownix Medical Inc, Teleflex Incorporated, Medtronics Plc, DePay Synthes, Tricumed Medizintechnik GmbH, Smiths Group Plc, Summit Medical Group, B Braun Melsungen AG, Becton, Dickinson & Company and Fresenius Medical Care AG & Co. KGaA. To gain competitive advantage these companies investing heavily in R&D for devolving fully programmable ITDD which can be fully implanted within the body and is safe for use coupled with the ability to control the flow of the drug delivery.
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.4.1. Assumptions
1.4.2. Forecast parameters
1.5. Data sources
1.5.1. Primary
1.5.2. Secondary
2. Executive Summary
2.1. 360° summary
2.2. Product Type
2.3. Application
3. Market overview
3.1. Market segmentation & definitions
3.2. Key takeaways
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of consumers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of new entrants
3.3.4. Threat of substitutes
3.3.5. Competitive rivalry in the market
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Technology landscape
3.6. Regulatory landscape
3.7. Patent landscape
3.8. Market value chain analysis
3.8.1. Stress point analysis
3.9. Strategic overview
4. Intrathecal Drug Delivery Systems Market, by Product
4.1. Externalized and connected to a pump
4.1.1. Market size and forecast, by region, 2016-2026
4.1.2. Comparative market share analysis, 2018 & 2026
4.2. Fully Implanted
4.2.1. Market size and forecast, by region, 2016-2026
4.2.2. Comparative market share analysis, 2018 & 2026
5. Intrathecal Drug Delivery Systems Market, by Application
5.1. Pain Management
5.1.1. Market size and forecast, by region, 2016-2026
5.1.2. Comparative market share analysis, 2018 & 2026
5.2. Spasticity Management
5.2.1. Market size and forecast, by region, 2016-2026
5.2.2. Comparative market share analysis, 2018 & 2026
6. Intrathecal Drug Delivery Systems Market, by Region
6.1. North America
6.1.1. Market size and forecast, by Product, 2016-2026
6.1.2. Market size and forecast, by application, 2016-2026
6.1.3. Market size and forecast, by country, 2016-2026
6.1.4. Comparative market share analysis, 2018 & 2026
6.1.5. U.S.
6.1.5.1. Market size and forecast, by Product, 2016-2026
6.1.5.2. Market size and forecast, by application, 2016-2026
6.1.5.3. Comparative market share analysis, 2018 & 2026
6.1.6. Canada
6.1.6.1. Market size and forecast, by Product, 2016-2026
6.1.6.2. Market size and forecast, by application, 2016-2026
6.1.6.3. Comparative market share analysis, 2018 & 2026
6.1.7. Mexico
6.1.7.1. Market size and forecast, by Product, 2016-2026
6.1.7.2. Market size and forecast, by application, 2016-2026
6.1.7.3. Comparative market share analysis, 2018 & 2026
6.2. Europe
6.2.1. Market size and forecast, by Product, 2016-2026
6.2.2. Market size and forecast, by application, 2016-2026
6.2.3. Market size and forecast, by country, 2016-2026
6.2.4. Comparative market share analysis, 2018 & 2026
6.2.5. Germany
6.2.5.1. Market size and forecast, by Product, 2016-2026
6.2.5.2. Market size and forecast, by application, 2016-2026
6.2.5.3. Comparative market share analysis, 2018 & 2026
6.2.6. Spain
6.2.6.1. Market size and forecast, by Product, 2016-2026
6.2.6.2. Market size and forecast, by application, 2016-2026
6.2.6.3. Comparative market share analysis, 2018 & 2026
6.2.7. France
6.2.7.1. Market size and forecast, by Product, 2016-2026
6.2.7.2. Market size and forecast, by application, 2016-2026
6.2.7.3. Comparative market share analysis, 2018 & 2026
6.2.8. Italy
6.2.8.1. Market size and forecast, by Product, 2016-2026
6.2.8.2. Market size and forecast, by application, 2016-2026
6.2.8.3. Comparative market share analysis, 2018 & 2026
6.2.9. Rest of the Europe
6.2.9.1. Market size and forecast, by Product, 2016-2026
6.2.9.2. Market size and forecast, by application, 2016-2026
6.2.9.3. Comparative market share analysis, 2018 & 2026
6.3. Asia-Pacific
6.3.1. Market size and forecast, by Product, 2016-2026
6.3.2. Market size and forecast, by application, 2016-2026
6.3.3. Market size and forecast, by country, 2016-2026
6.3.4. Comparative market share analysis, 2018 & 2026
6.3.5. China
6.3.5.1. Market size and forecast, by Product, 2016-2026
6.3.5.2. Market size and forecast, by application, 2016-2026
6.3.5.3. Comparative market share analysis, 2018 & 2026
6.3.6. Japan
6.3.6.1. Market size and forecast, by Product, 2016-2026
6.3.6.2. Market size and forecast, by application, 2016-2026
6.3.6.3. Comparative market share analysis, 2018 & 2026
6.3.7. India
6.3.7.1. Market size and forecast, by Product, 2016-2026
6.3.7.2. Market size and forecast, by application, 2016-2026
6.3.7.3. Comparative market share analysis, 2018 & 2026
6.3.8. Australia
6.3.8.1. Market size and forecast, by Product, 2016-2026
6.3.8.2. Market size and forecast, by application, 2016-2026
6.3.8.3. Comparative market share analysis, 2018 & 2026
6.3.9. South Korea
6.3.9.1. Market size and forecast, by Product, 2016-2026
6.3.9.2. Market size and forecast, by application, 2016-2026
6.3.9.3. Comparative market share analysis, 2018 & 2026
6.3.10. Rest of the Asia Pacific
6.3.10.1. Market size and forecast, by Product, 2016-2026
6.3.10.2. Market size and forecast, by application, 2016-2026
6.3.10.3. Comparative market share analysis, 2018 & 2026
6.4. LAMEA
6.4.1. Market size and forecast, by Product, 2016-2026
6.4.2. Market size and forecast, by application, 2016-2026
6.4.3. Market size and forecast, by country, 2016-2026
6.4.4. Comparative market share analysis, 2018 & 2026
6.4.5. Brazil
6.4.5.1. Market size and forecast, by Product, 2016-2026
6.4.5.2. Market size and forecast, by application, 2016-2026
6.4.5.3. Comparative market share analysis, 2018 & 2026
6.4.6. Saudi Arabia
6.4.6.1. Market size and forecast, by Product, 2016-2026
6.4.6.2. Market size and forecast, by application, 2016-2026
6.4.6.3. Comparative market share analysis, 2018 & 2026
6.4.7. South Africa
6.4.7.1. Market size and forecast, by Product, 2016-2026
6.4.7.2. Market size and forecast, by application, 2016-2026
6.4.7.3. Comparative market share analysis, 2018 & 2026
6.4.8. Rest of LAMEA
6.4.8.1. Market size and forecast, by Product, 2016-2026
6.4.8.2. Market size and forecast, by application, 2016-2026
6.4.8.3. Comparative market share analysis, 2018 & 2026
7. Company profiles
7.1. Flownix Medical Inc
7.1.1. Business overview
7.1.2. Financial performance
7.1.3. Product portfolio
7.1.4. Recent strategic moves & developments
7.1.5. SWOT analysis
7.2. Teleflex Incorporated
7.2.1. Business overview
7.2.2. Financial performance
7.2.3. Product portfolio
7.2.4. Recent strategic moves & developments
7.2.5. SWOT analysis
7.3. Medtronics Plc
7.3.1. Business overview
7.3.2. Financial performance
7.3.3. Product portfolio
7.3.4. Recent strategic moves & developments
7.3.5. SWOT analysis
7.4. DePay Synthes
7.4.1. Business overview
7.4.2. Financial performance
7.4.3. Product portfolio
7.4.4. Recent strategic moves & developments
7.4.5. SWOT analysis
7.5. Tricumed Medizintechnik GmbH
7.5.1. Business overview
7.5.2. Financial performance
7.5.3. Product portfolio
7.5.4. Recent strategic moves & developments
7.5.5. SWOT analysis
7.6. Smiths Group Plc
7.6.1. Business overview
7.6.2. Financial performance
7.6.3. Product portfolio
7.6.4. Recent strategic moves & developments
7.6.5. SWOT analysis
7.7. Summit Medical Group.
7.7.1. Business overview
7.7.2. Financial performance
7.7.3. Product portfolio
7.7.4. Recent strategic moves & developments
7.7.5. SWOT analysis
7.8. B Braun Melsungen AG,
7.8.1. Business overview
7.8.2. Financial performance
7.8.3. Product portfolio
7.8.4. Recent strategic moves & developments
7.8.5. SWOT analysis
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
